The European Medicines Agency (EMA) has begun an evaluation of a conditional marketing authorization application for the Skycovion (GBP510) COVID-19 vaccine candidate from SK Chemicals GmbH.
Skycovion is a recombinant protein-based vaccine with adjuvant from GSK.
In its filing, SK Chemicals provided data on how efficacious the vaccine is at creating antibodies against wild-type COVID-19. In addition, the company shared safety and quality data with the EMA.
Skycovion won approval for the vaccine in South Korea in June.
After the Committee for Medicinal Products for Human Use (CHMP) reviews the application, the European Commission will make a legally binding decision.A unique vaccine
Skycovion is a recombinant protein-based vaccine based on the genetically produced modified spike protein of the Wuhan stream of SARS-CoV-2. The vaccine uses nanoparticles to encode for the spike protein.
SK Chemicals is headquartered in Seoul, South Kor…